陈琦：靶向药物在不同瘤种中的biomarker一样吗？

参考文献：

[1]阎金杉,赵明芳,黄婕.精准诊断为导向，异病同治探索之路，泛瘤种免疫及靶向治疗的思考——评Ⅱ期伞式平台试验（TAPISTRY）研究[J].循证医学,2023,23(01):12-16.

[2]Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54-59.

[3]Rothenberg ML, LaFleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol. 2005;23(36):9265-9274. 

[4]Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer ［J］. Cancer Res, 2006, 66(8): 3992-3995.

[5]di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer ［J］. J Clin Oncol, 2008, 26(35): 5705-5712. 

[6]Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

[7]Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893–1901 (2012).

[8]Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33, 4032–4038 (2015).

[9]Abu-Rustum N, Yashar C, Arend R, et al. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(2):181-209. doi:10.6004/jnccn.2023.0006

[10]León-Castillo A, De Boer S M, Powell M E, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy[J]. Journal of Clinical Oncology, 2020, 38(29): 3388-3397.

[11]Musacchio L, Caruso G, Pisano C, et al. PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives. Cancer Manag Res. 2020;12:6123-6135. Published 2020 Jul 22.

[12]Baurain J F, Chon H S, Pepin J T, et al. Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status.[J]. Journal of Clinical Oncology, 2024.